Article info
PDFOriginal research
Feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer during COVID-19 pandemic
- Correspondence to Dr Safak Yilmaz Baran, Baskent Universitesi Adana Uygulama ve Arastirma Merkezi, Adana 01120, Turkey; safakyilmazbaran{at}gmail.com
Citation
Feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer during COVID-19 pandemic
Publication history
- Received February 8, 2021
- Revision received April 5, 2021
- Accepted April 8, 2021
- First published April 15, 2021.
Online issue publication
April 24, 2022
Article Versions
- Previous version (7 June 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage